Abstract
Anaphylaxis resulting from insect stings is estimated to affect 0.3–3% of the population and is responsible for at least 40 deaths a year in the United States. In addition, increasing numbers of reactions are caused by stings of the fire ant, a nonwinged Hymenoptera present primarily in the southeastern United States. Anaphylactic symptoms are typical of those occurring from any cause. The majority of reactions in children are mild, with dermal (hives, angioedema) symptoms only. The more severe reactions, such as shock and loss of consciousness, can occur at any age, but are relatively more common in adults. After an initial anaphylactic reaction, about 60% of unselected people will continue to have reactions from subsequent re-stings. The natural history of this disease process is influenced by age and severity of anaphylaxis. Children who had dermal reactions only have a very benign course and are unlikely to have recurrent re-sting allergic reactions. People who have had severe symptoms are more likely to have re-sting reactions, usually of similar intensity. People with a history of sting anaphylaxis and positive venom skin tests should have epinephrine available and are candidates for subsequent venom immunotherapy (VIT), which provides almost 100% protection against re-sting reactions. Recommendations for the duration of VIT are still evolving. VIT can be stopped if skin-test reactions become negative; for most people, 3–5 yr of VIT appears adequate, despite the persistence of positive tests. Individuals who have had life-threatening reactions, such as loss of consciousness, and retain positive skin tests should receive VIT indefinitely.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Suggested Reading
American Academy of Allergy, Asthma and Immunology Position Statement. Report from the Committee on Insects. J Allergy Clin Immunol 1998;101:573–575.
DeShazo RD, Butcher BT, Banks WA. Reactions to the stings of the imported fire ant. N Engl J Med 1990;313:462–466.
Golden DB, Kagey-Sobotka A, Norman PS, et al. Insect sting allergy with negative venom skin test responses. J Allergy Clin Immunol 2001;107:897–901.
Golden DBK, Kwiterovich KA, Kagey-Sobotka A, Lichtenstein LM. Discontinuing venom immunotherapy: extended observations. J Allergy Clin Immunol 1998;101:298–305.
Kemp SF, deShazo RD, Moffitt JE, et al. Expanding habitat of the imported fire ant (Solenopsis invicta): a public health concern, J Allergy Clin Immunol 2000; 105:683–691.
Lantner R, Reisman RE. Clinical and immunologic features and subsequent course of patients with severe insect-sting anaphylaxis. J Allergy Clin Immunol 1989;84:900–906.
Lerch E, Müller UR. Long-term protection after stopping venom immunotherapy; results of re-stings in 200 patients. J Allergy Clin Immunol 1998;101:606–612.
Lockey RF, Turkeltaub PC, Bair-Warren IA, et al. The Hymenoptera venom study I, 1979–1982: demographics and history sting data. J Allergy Clin Immunol 1988;82:370–381.
Mauriello PM, Barde SH, Georgitis JW, Reisman RE. Natural history of large location reactions from stinging insects. J Allergy Clin Immunol 1984;74:494–498.
McKenna WR. Killer bees: what the allergist should know. Pediatr Asthma Allergy Immunol 1992;4:275–285.
Moffitt JE, Golden DBK, Reisman RE, et al. Stinging insect hypersensitivity: A practice parameter update. J Allergy Clin Immunol 2004;114:869–886.
Reisman RE. Natural history of insect sting allergy: relationship of severity of symptoms of initial sting anaphylaxis to re-sting reactions. J Allergy Clin Immunol 1992;90:335–339.
Reisman RE. Venom hypersensitivity. J Allergy Clin Immunol 1994;94:651–658.
Reisman RE. Insect sting allergy: the dilemma of the negative skin test reactor. J Allergy Clin Immunol 2001;107:781–782.
Reisman RE, Livingston A. Venom immunotherapy; 10 years of experience with administration of single venoms and 50 mcg maintenance doses. J Allergy Clin Immunol 1992;89:1189–1195.
Valentine MD, Schuberth KC, Kagey-Sobotka A, et al. The value of immunotherapy with venom in children with allergy to insect stings. N Engl J Med 1991;323:1601–1603.
van Halteren HK, van der Linden PWG, Burgers JA, Bartelink AKM. Discontinuation of yellow jacket venom immunotherapy. Follow up of 75 patients by means of deliberate sting challenge. J Allergy Clin Immunol 1997;100:767–770.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2007 Humana Press, Totowa, NJ
About this chapter
Cite this chapter
Reisman, R.E. (2007). Insect Sting Allergy. In: Lieberman, P., Anderson, J.A. (eds) Allergic Diseases. Current Clinical Practice. Humana Press. https://doi.org/10.1007/978-1-59745-382-0_6
Download citation
DOI: https://doi.org/10.1007/978-1-59745-382-0_6
Publisher Name: Humana Press
Print ISBN: 978-1-58829-603-0
Online ISBN: 978-1-59745-382-0
eBook Packages: MedicineMedicine (R0)